Safety and Efficacy Study of CC312 for Moderate to Severe SLE

NCT07177911 · clinicaltrials.gov ↗

PHASE1

Phase

RECRUITING

Status

32

Enrollment

INDUSTRY

Sponsor class

Conditions

SLE - Systemic Lupus Erythematosus

Interventions

DRUG: CC312
DRUG: Placebo

Sponsor

CytoCares Inc